Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed adenocarcinoma of the prostate~  * Metastatic disease by imaging or clinical examination~* Hormone-refractory disease, defined as prostate-specific antigen (PSA) level \> 10 µg/L AND rising between 2 sequential measurements~* Testosterone within castration levels by orchiectomy or medical castration comprising luteinizing hormone-releasing hormone (LHRH) analogues~PATIENT CHARACTERISTICS:~Age~* Over 18~Performance status~* WHO 0-2~Life expectancy~* Not specified~Hematopoietic~* Neutrophil count ≥ 1,500/mm\^3~* Hemoglobin ≥ 11.0 g/dL~* Platelet count ≥ 100,000/mm\^3~Hepatic~* ALT and AST ≤ 2.5 times upper limit of normal (ULN)~* Bilirubin normal~* Alkaline phosphatase ≤ 6 times ULN (unless due to the presence of extensive bone disease)~* No serious liver disease~Renal~* Creatinine ≤ 1.5 times ULN~Cardiovascular~* No ischemic or thromboembolic cardiac disease~* No myocardial infarction within the past 12 months~* No other serious cardiac disease~Pulmonary~* No pulmonary emboli~Immunologic~* No active infection~* No autoimmune disease, including any of the following:~  * Lupus~ * Scleroderma~ * Rheumatoid polyarthritis~Other~* No active peptic ulcer~* No unstable diabetes mellitus~* No contraindication to corticosteroids~* No other malignant disease within the past 5 years except basalioma~* No functional iron deficiency (i.e., transferrin saturation \< 20%) that cannot be treated with iron supplementation~* No other serious illness or medical condition~PRIOR CONCURRENT THERAPY:~Biologic therapy~* More than 2 months since prior recombinant human epoetin alfa or any other erythropoiesis-stimulating drug~Chemotherapy~* At least 3 weeks since prior estramustine~Endocrine therapy~* See Disease Characteristics~* At least 3 weeks since prior antiandrogen treatment~* Concurrent chemical castration with LHRH allowed provided patient has begun treatment prior to study entry~  * No initiation of chemical castration therapy during study treatment~Radiotherapy~* No prior radiotherapy to \> 25% of bone marrow~* No prior radioisotope therapy~* Concurrent local palliative radiotherapy for pain allowed~Surgery~* See Disease Characteristics~* At least 4 weeks since prior surgery~Other~* No other prior cytostatic treatment~* Concurrent bisphosphonates allowed provided patient has begun treatment prior to study entry~  * No initiation of bisphosphonates during study treatment

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive docetaxel IV over 1 hour on days 1 and 15 and oral prednisone once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- Arm II (Type: EXPERIMENTAL): Patients receive docetaxel IV over 1 hour on day 1 and prednisone once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete